Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma

BACKGROUND: Tazemetostat is a selective and orally available inhibitor of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and epigenetic regulator of cellular differentiation programs. We carried out a phase I study of tazemetostat in Japanese patients with relapsed or refractory B‐c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Sci
Auteurs principaux: Munakata, Wataru, Shirasugi, Yukari, Tobinai, Kensei, Onizuka, Makoto, Makita, Shinichi, Suzuki, Rikio, Maruyama, Dai, Kawai, Hidetsugu, Izutsu, Koji, Nakanishi, Tadashi, Shiba, Sari, Hojo, Seichiro, Ando, Kiyoshi
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2021
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7935786/
https://ncbi.nlm.nih.gov/pubmed/33492746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14822
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires